Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

UBS upgraded its rating on vaccine maker Moderna MRNA, -1.64% to buy from neutral on valuation grounds, but cut its price target to $191 from $221. “We acknowledge the uncertainty around the commercial/endemic COVID market and uncertainty around '23 revenues, which has been a key investor focus and headwind,” said analysts led by Eliana Merle.

UBS upgrades Moderna to buy while cutting price target

Moderna shares delivered enormous gains during the first year and a half of the pandemic. Since then, though, the stock has suffered as investors worry about declining revenues.

Wall Street Says This Beaten-Down Stock May Climb Nearly 78%. Is That Too Optimistic?

Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. The company expects the vaccine to be available for the fall season, provided the FDA authorizes the same.

Moderna (MRNA) Seeks FDA Nod for Updated COVID-19 Vaccine

Moderna said on Thursday it has completed the submission of a regulatory application to the U.S. Food and Drug Administration for its updated COVID-19 vaccine to target subvariant XBB.1.5.

Moderna files for US FDA authorization of updated COVID vaccine

Moderna said the submission is based on the FDA's recommendation that vaccine makers update their jabs to target omicron subvariant XBB.1.5.

Moderna files for FDA approval of updated Covid vaccine for fall

Preliminary clinical data demonstrated a robust immune response by the company's XBB.1.5 monovalent vaccine against XBB descendent lineage viruses Pending authorization, Moderna's updated COVID-19 vaccine would be available in time for fall vaccination Supply readiness follows months of manufacturing to ensure timely and ample supply CAMBRIDGE, MA / ACCESSWIRE / June 22, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has completed submission of a regulatory application to the U.S. Food and Drug Administration for its updated COVID-19 vaccine containing spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 (mRNA-1273.815). "The agility of our mRNA platform has enabled us to update Spikevax, Moderna's COVID-19 vaccine, to target XBB variants with speed and clinical rigor," said Stéphane Bancel, CEO of Moderna.

Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine

VanEck Vectors Biotech ETF

First Trust Morningstar Dividend Leaders Index Fund

First Trust Nasdaq Pharmaceuticals ETF 

Amplify Treatments Testing & Advancements ETF

iShares Core High Dividend ETF

Invesco Nasdaq Biotechnology ETF

Horizon Kinetics Medical ETF

Novavax

Pfizer

Invesco Dynamic Pharmaceuticals ETF

The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.

Biotech ETFs in Focus on Covid Vaccines' Fall Rollout

Denali Therapeutics

Foghorn Therapeutics

Seres Therapeutics

Omega Therapeutics

Sana Biotechnology

Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively The company emerges after two years of platform development with an initial commitment of $50 million from Flagship Pioneering Empress has identified and characterized 15 potential small molecule drugs in less than two years; it expects to file multiple Investigational New Drug (IND) applications within the next 24 months Murray McKinnon, Ph.D., former Global Head of J&J's World Without Disease Accelerator and Head of Immunology Discovery within Janssen Pharmaceuticals, appointed Chief Scientific Officer CAMBRIDGE, Mass.

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

The pandemic darling and mRNA pioneer is still trying to conjure a follow-up act. “Science doesn't move in a straight line,” says Stéphane Bancel, “especially with cutting-edge science that no human has done before you.

Moderna became a hero with its COVID-19 vaccine—now comes the hard part

The FDA's strain selection puts Pfizer, Moderna and Novavax on track to deliver updated coronavirus shots in time for the fall.

Pfizer, Moderna and Novavax gear up for fall Covid vaccine rollout with an important head start

Advance Auto Parts

Ally Financial

DISH Network

Nutrien

Signet Jewelers

AT&T

The key to making profits in the markets has been to buy large-cap growth stocks, and sell value stocks. At least, that's what it seems like, when you take into account that the surge of the S&P 500 index year-to-date is largely attributable to big gains among big tech stocks.

7 Value Stocks to Dump Before They Decline Even Further

BioNTech SE

The U.S. Food and Drug Administration (FDA) said on Friday it has advised manufacturers that are updating their COVID-19 vaccines to develop monovalent shots to target the XBB.1.5 subvariant.

US FDA advises COVID vaccine makers to develop shots aimed at XBB.1.5 variant

The FDA's decision is a win for vaccine makers Pfizer, Moderna and Novavax, which have all been developing versions of their Covid shots to target XBB.1.5.

FDA recommends that updated Covid shots target omicron subvariant XBB.1.5 this fall

An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.

FDA Panel Endorses Updating COVID Jab to Target XBB Strain

Today's vaccines still contain the original coronavirus strain, the one that started the pandemic — even though that was long ago supplanted by mutated versions as the virus rapidly evolves.

FDA advisers endorse updating COVID vaccines to target latest omicron strain

Moderna, Inc. (NASDAQ:MRNA ) Goldman Sachs 44th Annual Global Healthcare Conference June 14, 2023 7:40 PM ET Company Participants Jamey Mock - CFO Lavina Talukdar - Head of IR Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon, everyone. Thanks so much for joining us, I am Salveen Richter, Biotechnology Analyst at Goldman Sachs.

Moderna, Inc. (MRNA) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

C3.ai

Beyond Meat

GameStop

Mullen Automotive

NVIDIA

Lordstown Motors

As we pass the halfway mark of 2023, it's time to consider which stocks to sell in June. If investors continue to have trouble understanding whether the markets are due for another correction soon it's for good reason.

7 Stocks to Sell in June Before They Crash and Burn

Moderna, Inc. is expected to have negative profits in 2023, impacting the company's strong net-cash position. Late-2023 and 2024 are worth paying close attention to. Specifically, whether the company can launch its RSV vaccine. The company needs to show a long-term ability to generate $10+ billion in revenue, making it a valuable investment.

Moderna's Weakness Is Your Opportunity

Medical Properties Trust

United Continental Hlds

With the stock market rising quickly, many companies have become expensive. Understandably, investors are considering value stocks as an alternative to frothy growth picks.

Get Out Now! 3 Value Stocks That Are Poised to Plunge.

Amazon

Medtronic

AI stocks don't necessarily have to be technology companies. Some e-commerce and healthcare companies are investing in AI -- this can benefit their businesses and investors over time.

3 Top AI Stocks to Buy Hand Over Fist

Moderna is developing a personalized cancer vaccine in partnership with Merck. Moderna recently reported clinical-trial results that suggest its cancer vaccine does a lot to prevent skin cancer tumors from returning after they've been surgically removed.

Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now?

Moderna, Inc. (NASDAQ:MRNA ) Jefferies Global Healthcare Conference June 8, 2023 10:30 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Yee - Jefferies Michael Yee Well, thank you, everyone, for joining us on our next session up here. I think our next guest needs no introduction.

Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference (Transcript)

Alphabet

Palantir Technologies

As artificial-intelligence tools show promise in transforming healthcare, technology companies, healthcare providers, drugmakers and other players are also focused on its potentially damaging side effects.

As AI advances in healthcare, industry players wrestle with its risks

Biotech firm Promosome LLC sued Moderna , Pfizer and BioNTech , in federal court in San Diego, California, on Tuesday, accusing their COVID-19 vaccines of infringing a patent related to messenger RNA technology.

Moderna, Pfizer hit with new patent lawsuits over COVID vaccines

Updated data from a mid-stage study showed that Moderna (MRNA)/Merck's personalized cancer vaccine combined with Keytruda reduces the skin cancer's spreading by 65% in melanoma patients.

News for Moderna Stock (MRNA)